All Tox In Focus volumes
Tox In Focus
|
Focused Clinical Reference
Vol. 32  ·  Stimulant Medications  ·  July 2026
STIMULANTS
Prescription amphetamines and methylphenidates: metabolites and how they screen

Prescription stimulants split into two families: amphetamine-type agents (amphetamine, dextroamphetamine, lisdexamfetamine, methamphetamine, phentermine, benzphetamine) and methylphenidate-type agents (methylphenidate, dexmethylphenidate). They differ in metabolism and in how they screen: amphetamine immunoassays detect the amphetamine family but not methylphenidate, so LC-MS/MS is needed to identify the specific agent.1

Why This Matters Now

Interpretation requires knowing the family and its metabolites: several amphetamine-type prescriptions produce amphetamine (and some produce methamphetamine), while methylphenidate produces ritalinic acid and is invisible to amphetamine screens. Amphetamine immunoassays are also prone to false positives from unrelated drugs, so a positive should be confirmed.2

⚠ A methylphenidate-prescribed patient can screen negative on amphetamine immunoassay, and an amphetamine screen positive can be a cross-reactant. Confirm the specific stimulant by LC-MS/MS before acting.
Clinical Presentation
INTOXICATION
Alertness, reduced fatigue, euphoria
Tachycardia, hypertension
Agitation, anxiety, insomnia
Appetite suppression
Psychosis, hyperthermia (high dose)
WITHDRAWAL
Fatigue, hypersomnia
Depressed mood
Increased appetite
Irritability
Craving
Important: The amphetamine immunoassay detects the amphetamine family but not methylphenidate, and it cross-reacts with many unrelated drugs. Both false negatives (methylphenidate) and false positives are common; confirm by LC-MS/MS.
UDT Considerations

LC-MS/MS identifies the specific stimulant and metabolite. Key relationships: benzphetamine can yield methamphetamine and amphetamine, dextroamphetamine and lisdexamfetamine yield amphetamine, and methylphenidate yields ritalinic acid.3 For methamphetamine positives, d/l isomer testing distinguishes illicit from medicinal sources.3

Clinical Guidance
  • Confirm amphetamine-class positives with LC-MS/MS; screens cross-react and can be false positives.2
  • Do not rely on an amphetamine screen for methylphenidate; order methylphenidate-specific testing.1
  • Match the detected analyte to the prescribed agent's expected metabolites.3
  • Use d/l isomer testing for methamphetamine when the source is in question.
  • Account for urinary pH and CYP2D6 variation affecting levels and windows.
Point-of-Care Testing Availability
Available strips
Amphetamine immunoassays detect amphetamine-type stimulants but miss methylphenidate.
Clinical use
They also cross-react with many non-amphetamine drugs (false positives).
Limitations
LC-MS/MS identifies the specific stimulant and metabolite.
STIMULANTS  |  Clinical & Program Guidance
Tox In Focus Vol. 32  ·  July 2026  ·  Page 2 of 2
Interpreting the Test Result
▲  If Testing Is Positive

Match analyte to prescription. The detected amphetamine or methylphenidate should fit the prescribed agent's metabolism.3

Screen positives need confirmation. Amphetamine immunoassays cross-react; confirm the specific drug by LC-MS/MS.2

Methamphetamine source. Consider d/l isomer testing to separate illicit from medicinal methamphetamine.

Prescription Stimulants: Analytes and Windows
Medication (generic)Measured analyte(s)Urine window
Amphetamine (Adderall)Amphetamine2-7 days
DextroamphetamineAmphetamine2-7 days
Lisdexamfetamine (Vyvanse)Amphetamine2-7 days
Methamphetamine (Desoxyn)Methamphetamine (+ amphetamine)2-7 days
Benzphetamine (Didrex)Methamphetamine, amphetamine2-7 days
Phentermine (Adipex-P)Phentermine2-7 days (limited data)
Methylphenidate (Ritalin/Concerta)Methylphenidate, ritalinic acid1-2 days
Dexmethylphenidate (Focalin)Methylphenidate, ritalinic acid1-2 days

Amphetamine-type agents produce amphetamine (some also methamphetamine); methylphenidate-type produce ritalinic acid and are missed by amphetamine screens.

Key References
  1. Adderall and stimulant prescribing information. Manufacturer package inserts. 2016.
  2. Reisfield GM, Goldberger BA, Bertholf RL. 'False-positive' and 'false-negative' test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952.
  3. Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs. Effective February 1, 2024.
DISCLAIMER: This document is intended for clinical reference and educational purposes only. It does not constitute medical, legal, or professional advice and should not replace independent clinical or programmatic judgment. Content reflects published data available at time of preparation. ToxiPharm LLC makes no warranties regarding completeness or applicability in all settings.  |   © 2026 ToxiPharm LLC  |  toxipharm.org
Back to Tox In Focus ToxiPharm home →